TY - JOUR T1 - Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. AU - Klein,Nicola P, AU - Stockwell,Melissa S, AU - Demarco,Maria, AU - Gaglani,Manjusha, AU - Kharbanda,Anupam B, AU - Irving,Stephanie A, AU - Rao,Suchitra, AU - Grannis,Shaun J, AU - Dascomb,Kristin, AU - Murthy,Kempapura, AU - Rowley,Elizabeth A, AU - Dalton,Alexandra F, AU - DeSilva,Malini B, AU - Dixon,Brian E, AU - Natarajan,Karthik, AU - Stenehjem,Edward, AU - Naleway,Allison L, AU - Lewis,Ned, AU - Ong,Toan C, AU - Patel,Palak, AU - Konatham,Deepika, AU - Embi,Peter J, AU - Reese,Sarah E, AU - Han,Jungmi, AU - Grisel,Nancy, AU - Goddard,Kristin, AU - Barron,Michelle A, AU - Dickerson,Monica, AU - Liao,I-Chia, AU - Fadel,William F, AU - Yang,Duck-Hye, AU - Arndorfer,Julie, AU - Fireman,Bruce, AU - Griggs,Eric P, AU - Valvi,Nimish R, AU - Hallowell,Carly, AU - Zerbo,Ousseny, AU - Reynolds,Sue, AU - Ferdinands,Jill, AU - Wondimu,Mehiret H, AU - Williams,Jeremiah, AU - Bozio,Catherine H, AU - Link-Gelles,Ruth, AU - Azziz-Baumgartner,Eduardo, AU - Schrag,Stephanie J, AU - Thompson,Mark G, AU - Verani,Jennifer R, Y1 - 2022/03/04/ PY - 2022/3/3/entrez PY - 2022/3/4/pubmed PY - 2022/3/15/medline SP - 352 EP - 358 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 71 IS - 9 N2 - The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, and 16-17 years (1-3). Limited real-world data on 2-dose mRNA vaccine effectiveness (VE) in persons aged 12-17 years (referred to as adolescents in this report) have also indicated high levels of protection against SARS-CoV-2 (the virus that causes COVID-19) infection and COVID-19-associated hospitalization (4-6); however, data on VE against the SARS-CoV-2 B.1.1.529 (Omicron) variant and duration of protection are limited. Pfizer-BioNTech VE data are not available for children aged 5-11 years. In partnership with CDC, the VISION Network* examined 39,217 emergency department (ED) and urgent care (UC) encounters and 1,699 hospitalizations† among persons aged 5-17 years with COVID-19-like illness across 10 states during April 9, 2021-January 29, 2022,§ to estimate VE using a case-control test-negative design. Among children aged 5-11 years, VE against laboratory-confirmed COVID-19-associated ED and UC encounters 14-67 days after dose 2 (the longest interval after dose 2 in this age group) was 46%. Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 83% and 76%, respectively; VE ≥150 days after dose 2 was 38% and 46%, respectively. Among adolescents aged 16-17 years, VE increased to 86% ≥7 days after dose 3 (booster dose). VE against COVID-19-associated ED and UC encounters was substantially lower during the Omicron predominant period than the B.1.617.2 (Delta) predominant period among adolescents aged 12-17 years, with no significant protection ≥150 days after dose 2 during Omicron predominance. However, in adolescents aged 16-17 years, VE during the Omicron predominant period increased to 81% ≥7 days after a third booster dose. During the full study period, including pre-Delta, Delta, and Omicron predominant periods, VE against laboratory-confirmed COVID-19-associated hospitalization among children aged 5-11 years was 74% 14-67 days after dose 2, with wide CIs that included zero. Among adolescents aged 12-15 and 16-17 years, VE 14-149 days after dose 2 was 92% and 94%, respectively; VE ≥150 days after dose 2 was 73% and 88%, respectively. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations, including a booster dose for those aged 12-17 years. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/35239634/Effectiveness_of_COVID_19_Pfizer_BioNTech_BNT162b2_mRNA_Vaccination_in_Preventing_COVID_19_Associated_Emergency_Department_and_Urgent_Care_Encounters_and_Hospitalizations_Among_Nonimmunocompromised_Children_and_Adolescents_Aged_5_17_Years___VISION_Network_10_States_April_2021_January_2022_ DB - PRIME DP - Unbound Medicine ER -